The Concepts, Diagnosis and Management of Early Imaging Changes after Therapy for Glioblastomas

Clinical Oncology

Volumn 24, Issue 3, 2012, Pages 216-227

  Sanghera, P ^a   Rampling, R ^b   Haylock, B ^c   Jefferies, S ^d   McBain, C ^e   Rees, J H ^f   Soh, C ^g   Whittle, I R ^h  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Glioblastoma; MRI; Pseudoprogression; Temozolomide

Indexed keywords

CARMUSTINE; FERUMOXYTOL; GADOLINIUM; HYDROXYUREA; METHIONINE C 11; TEMOZOLOMIDE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; DISEASE MARKER; GLIOBLASTOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTRON CAPTURE THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RADIATION NECROSIS;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; GLIOBLASTOMA; HUMANS;

EID: 84857922251     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.06.004     Document Type: Article

References (80)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Sanghera P., Perry J., Sahgal A., et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010, 37:36-42.
3. Harris FP, Jones PH, Burton KE, et al. An outcome review of the introduction of concomitant and adjuvant temozolomide with radiotherapy for glioblastoma in a UK centre. Abstract presented at the EORTC-EANO Conference, 27-28 March 2009, Budapest, Hungary.
4. de Wit M.C., de Bruin H.G., Eijkenboom W., et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004, 63:535-537.
5. Fiegler W., Langer M., Scheer M., Kazner E. Reversible computed tomographic changes following brain tumor irradiation induced by the "early-delayed reaction" after radiation. Radiologe 1986, 26:206-209.
6. Griebel M., Friedman H.S., Halperin E.C., et al. Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Med Pediatr Oncol 1991, 19:182-186.
7. Watne K., Hager B., Heier M., et al. Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations. Acta Oncol 1990, 29:891-895.
8. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
9. Taal W., Brandsma D., de Bruin H.G., et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113:405-410.
10. Clarke J.L., Iwamoto F.M., Sul J., et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009, 27:3861-3867.
11. Gerstner E.R., McNamara M.B., Norden A.D., et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009, 94:97-101.
12. Chaskis C., Neyns B., Michotte A., et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009, 72:423-428.
13. Jefferies S., Burton K., Jones P., et al. Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma. Clin Oncol (R Coll Radiol) 2007, 19(Suppl.):33.
14. Fabi A., Russillo M., Metro G., et al. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Res 2009, 29:2607-2610.
15. Roldán G.B., Scott J.N., McIntyre J.B., et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009, 36:617-622.
16. Hoffman W.F., Levin V.A., Wilson C.B. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 1979, 50:624-628.
17. Brandsma D., Stalpers L., Taal W., et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461.
18. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572-2578.
19. van den Bent M.J., Vogelbaum M.A., Wen P.Y., et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009, 27:2905-2908.
20. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
21. Yang I., Aghi M.K. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009, 6:648-657.
22. Macdonald D.R., Cascino T.L., Schold S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
23. Tsien C., Gomez-Hassan D., Ten Haken R.K., et al. Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: implications for conformal dose-escalation studies. Int J Radiat Oncol Biol Phys 2005, 62:328-332.
24. Cao Y., Tsien C.I., Shen Z., et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005, 23:4127-4136.
25. Wong C.S., Van der Kogel A.J. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 2004, 4:273-284.
26. Soussain C., Ricard D., Fike J.R., et al. CNS complications of radiotherapy and chemotherapy. Lancet 2009, 374:1639-1651.
27. Diserbo M., Agin A., Lamproglou I., et al. Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Can J Physiol Pharmacol 2002, 80:670-678.
28. Gregoire V., Sindic C., Gahbauer R.A., et al. Alteration of the blood-brain barrier after irradiation: implication in boron neutron capture therapy. Strahl Onkol 1993, 169:534-542.
29. Siegal T., Pfeffer M.R. Radiation-induced changes in the profile of spinal cord serotonin, prostaglandin synthesis, and vascular permeability. Int J Radiat Oncol Biol Phys 1995, 31:57-64.
30. Nakata H., Yoshimine T., Murasawa A., et al. Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats. Acta Neurochir 1995, 136:82-86.
31. Reese T.S., Karnovsky M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967, 34:207-217.
32. Brightman M.W., Reese T.S. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969, 40:648-677.
33. Papadopoulos M.C., Saadoun S., Binder D.K., et al. Molecular mechanisms of brain tumor edema. Neuroscience 2004, 129:1011-1020.
34. Janzer R.C., Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987, 325:253-257.
35. Hayashi Y., Nomura M., Yamagishi S.I., et al. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 1997, 19:13-26.
36. Lee S.W., Kim W.J., Park J.A., et al. Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 2006, 29:265-275.
37. Peña L.A., Fuks Z., Kolesnick R.N. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 2000, 60:321-327.
38. Li Y.Q., Chen P., Haimovitz-Friedman A., et al. Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Res 2003, 63:5950-5956.
39. Rodemann H.P., Baumann M., Bodis S., Dikomey E. Molecular radiation biology/oncology. Radiother Oncol 2004, 72:247-249.
40. Peña L.A., Fuks Z., Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol 1997, 53:615-621.
41. Sheline G.E., Wara W.M., Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980, 6:1215-1228.
42. Whittle I.R. The origins and management of peritumoural brain dysfunction. Neurosurg Quart 1992, 2:174-199.
43. Chamberlain M.C., Glantz M.J., Chalmers L., et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82:81-83.
44. Peca C., Pacelli R., Elefante A., et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?. Clin Neurol Neurosurg 2009, 111:331-334.
45. Ruben J.D., Dally M., Bailey M., et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499-508.
46. Burger P.C., Mahley M.S., Dudka L., et al. The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer 1979, 44:1256-1272.
47. Marks J.E., Baglan R.J., Prassad S.C., et al. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981, 7:243-252.
48. Debus J., Hug E.B., Liebsch N.J., et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 1997, 39:967-975.
49. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
50. Sugahara T., Korogi Y., Tomiguchi S., et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. Am J Neuroradiol 2000, 21:901-909.
51. Di Costanzo A., Pollice S., Trojsi F., et al. Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas. Radiol Med 2008, 113:134-143.
52. Gahramanov S., Raslan A.M., Muldoon L.L., et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011, 79:514-523.
53. Kumar A.J., Leeds N.E., Fuller G.N., et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000, 217:377-384.
54. Mullins M.E., Barest G.D., Schaefer P.W., et al. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. Am J Neuroradiol 2005, 26:1967-1972.
55. Biousse V., Newman N.J., Hunter S.B., et al. Diffusion weighted imaging in radiation necrosis. J Neurol Neurosurg Psychiatry 2003, 74:382-384.
56. Hein P.A., Eskey C.J., Dunn J.F., et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. Am J Neuroradiol 2004, 25:201-209.
57. Ando K., Ishikura R., Nagami Y., et al. Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions. Nippon Igaku Hoshasen Gakkai Zasshi 2004, 64:121-126.
58. Lichy M.P., Henze M., Plathow C., et al. Metabolic imaging to follow stereotactic radiation of gliomas: the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT. Rofo 2004, 176:1114-1121.
59. Plotkin M., Eisenacher J., Bruhn H., et al. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol 2004, 70:49-58.
60. Matsusue E., Fink J.R., Rockhill J.K., et al. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiol 2010, 52:297-306.
61. Yang I., Huh N.G., Smith Z.A., et al. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg Clin North Am 2010, 21:181-186.
62. Miyatake S.-I., Kawabata S., Nonoguchi N., et al. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol 2009, 11:430-436.
63. Albert F.K., Forsting M., Sartor K., et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994, 34:45-61.
64. Forsting M., Albert F.K., Kunze S., et al. Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 1993, 14:77-87.
65. Forsyth P.A., Petrov E., Mahallati H., et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol 1997, 15:2076-2081.
66. Perry J.R., Cairncross J.G. Glioma therapies: how to tell which work?. J Clin Oncol 2003, 21:3547-3549.
67. Lamborn K.R., Yung W.K., Chang S.M., et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008, 10:162-170.
68. Ballman K.V., Buckner J.C., Brown P.D., et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007, 9:29-38.
69. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
70. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260.
71. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
72. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
73. Iwamoto F.M., Abrey L.E., Beal K., et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73:1200-1206.
74. Zuniga R.M., Torcuator R., Jain R., et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009, 91:329-336.
75. Smith M.M., Thompson J.E., Castillo M., et al. MR of recurrent high-grade astrocytomas after intralesional immunotherapy. Am J Neuroradiol 1996, 17:1065-1071.
76. Prager J.M., Grenier Y., Cozzens J.W., et al. Serial CT and MR imaging of carmustine wafers. Am J Neuroradiol 2000, 21:119-123.
77. Mason W.P., Maestro R.D., Eisenstat D., et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007, 14:110-117.
78. McGirt M.J., Bulsara K.R., Cummings T.J., et al. Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. J Neurosurg 2003, 98:14-20.
79. Forsyth P.A., Kelly P.J., Cascino T.L., et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotatic biopsy useful?. J Neurosurg 1995, 82:436-444.
80. Tihan T., Barletta J., Parney I., et al. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?. Hum Pathol 2006, 37:272-282.